Strategic leadership Recent C-suite transition to Joanne Kotz as CEO signals a potential openness to partnerships and external collaborations to accelerate clinical programs in CNS RNAi, presenting an opportunity to align BD efforts with executive leadership and funding plans.

Funding momentum Series B funding of up to 97 million demonstrates strong investor confidence and available capital to support late-stage programs, enabling conversations around co-development, licensing, or strategic partnerships to advance CNS RNAi therapies.

Pipeline focus Wholly owned and partnered RNAi programs targeting Huntington’s disease, genetic epilepsy, and chronic pain create multiple entry points for collaborations, CRO support, or advisory relationships to de-risk and accelerate development timelines.

Clinical readiness Expansion of executive team and strategic hires in medical and financial leadership indicate a focus on clinical execution and governance, making it prudent to propose services around clinical operations, regulatory strategy, and program management.

Neuroscience specialization Proprietary di-siRNA brain and spinal cord targeting platform offers a distinctive value proposition for CNS-focused service providers, enabling sales conversations around platform collaboration, preclinical testing, biomarker development, and translational studies.